Why Do We Screen Newborn Infants for Cystic Fibrosis?
Open Access
- 8 July 2020
- journal article
- editorial
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (3), 56
- https://doi.org/10.3390/ijns6030056
Abstract
The introduction and widespread implementation of newborn bloodspot screening (NBS) for cystic fibrosis (CF) has offered earlier diagnosis and better outcomes for children with CF in many countries of the worldKeywords
This publication has 10 references indexed in Scilit:
- The Changing Face of Cystic Fibrosis and Its Implications for ScreeningInternational Journal of Neonatal Screening, 2020
- It All Depends What You Count—The Importance of Definitions in Evaluation of CF Screening PerformanceInternational Journal of Neonatal Screening, 2020
- Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot Screening for Cystic FibrosisInternational Journal of Neonatal Screening, 2020
- Pancreatitis-Associated Protein in Neonatal Screening for Cystic Fibrosis: Strengths and WeaknessesInternational Journal of Neonatal Screening, 2020
- Psychological Impact of NBS for CFInternational Journal of Neonatal Screening, 2020
- Processing Newborn Bloodspot Screening Results for CFInternational Journal of Neonatal Screening, 2020
- The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic FibrosisInternational Journal of Neonatal Screening, 2020
- Inconclusive Diagnosis after Newborn Screening for Cystic FibrosisInternational Journal of Neonatal Screening, 2020
- Newborn Screening for CF across the Globe—Where Is It Worthwhile?International Journal of Neonatal Screening, 2020
- History of Newborn Screening for Cystic Fibrosis—The Early YearsInternational Journal of Neonatal Screening, 2020